Mounjaro (tirzepatide) led to greater weight loss and better glucose control than high doses of Trulicity (dulaglutide), according to a study published April 4 in Annals of Internal Medicine. A common ...
Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment Mounjaro did not demonstrate superiority over Trulicity, its older GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback